RhumbLine Advisers
SCPH

RhumbLine Advisers’s scPharmaceuticals SCPH Stock Holding History

RhumbLine Advisers’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-54,641
Closed -$310K – 4169
2025
Q3 		$310K Buy
54,641
+141
+0.3% +$722 ﹤0.01% 2975
2025
Q2 		$208K Buy
54,500
+3,001
+6% +$9.32K ﹤0.01% 3211
2025
Q1 		$135K Buy
51,499
+8,945
+21% +$29.1K ﹤0.01% 3287
2024
Q4 		$151K Buy
42,554
+7,112
+20% +$27.2K ﹤0.01% 3332
2024
Q3 		$162K Sell
35,442
-2,488
-7% -$12K ﹤0.01% 3334
2024
Q2 		$165K Buy
37,930
+1,489
+4% +$6.54K ﹤0.01% 3332
2024
Q1 		$183K Buy
36,441
+756
+2% +$4.24K ﹤0.01% 3224
2023
Q4 		$224K Buy
35,685
+767
+2% +$4.39K ﹤0.01% 3124
2023
Q3 		$249K Buy
34,918
+956
+3% +$7.53K ﹤0.01% 3036
2023
Q2 		$346K Buy
+33,962
New +$354K ﹤0.01% 2923

RhumbLine Advisers's SCPH Position: Q4 2025 in Review

RhumbLine Advisers sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 54,641 shares — an estimated $310K sold.

RhumbLine Advisers first reported a position in SCPH in Q2 2023 and held it in 10 quarters. The position peaked at $346K in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

  • RhumbLine Advisers reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 54,641 scPharmaceuticals shares in Q4 2025, an estimated $310K.
  • RhumbLine Advisers first reported a position in scPharmaceuticals in Q2 2023 and held it in 10 quarters.
  • RhumbLine Advisers's scPharmaceuticals position peaked at $346K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on RhumbLine Advisers's 13F filing for Q4 2025, filed 13 Feb 2026.